(CE) Celanese - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1508701034
Stock: Polymers, Chemicals, Resins, Elastomers
Total Rating 31
Risk 81
Buy Signal -1.51
| Risk 5d forecast | |
|---|---|
| Volatility | 59.5% |
| Relative Tail Risk | -11.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -28.67 |
| Character TTM | |
|---|---|
| Beta | 1.239 |
| Beta Downside | 1.636 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.96% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: CE Celanese March 04, 2026
Celanese Corporation, a specialty chemicals company, produces and sells engineered polymers and other chemical products globally. The company operates through two segments: Engineered Materials and Acetyl Chain.
The Engineered Materials segment offers a wide range of advanced polymers, including liquid crystal polymers and polyoxymethylene, used in diverse sectors like automotive, medical, and consumer electronics. The Acetyl Chain segment manufactures chemicals such as acetic acid, vinyl acetate monomers, and emulsion polymers, which are key ingredients in products spanning from adhesives and coatings to textiles and pharmaceuticals. These products are foundational to numerous manufacturing processes.
Celanese distributes its products directly to customers, through distributors, and to original equipment manufacturers. Further research on ValueRay can provide deeper insights into Celaneses financial performance and market position.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: -1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.38 > 1.0 |
| NWC/Revenue: 21.06% < 20% (prev 12.57%; Δ 8.49% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.15b > Net Income -1.16b |
| Net Debt (206.0m) to EBITDA (292.0m): 0.71 < 3 |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (109.8m) vs 12m ago 0.37% < -2% |
| Gross Margin: 20.06% > 18% (prev 0.23%; Δ 1984 % > 0.5%) |
| Asset Turnover: 42.84% > 50% (prev 44.98%; Δ -2.13% > 0%) |
| Interest Coverage Ratio: -0.62 > 6 (EBITDA TTM 292.0m / Interest Expense TTM 769.0m) |
Altman Z'' 2.50
| A: 0.09 (Total Current Assets 5.69b - Total Current Liabilities 3.68b) / Total Assets 21.70b |
| B: 0.46 (Retained Earnings 9.88b / Total Assets 21.70b) |
| C: -0.02 (EBIT TTM -477.0m / Avg Total Assets 22.28b) |
| D: 0.53 (Book Value of Equity 9.10b / Total Liabilities 17.22b) |
| Altman-Z'' Score: 2.50 = A |
Beneish M -3.42
| DSRI: 0.62 (Receivables 922.0m/1.61b, Revenue 9.54b/10.28b) |
| GMI: 1.14 (GM 20.06% / 22.92%) |
| AQI: 0.92 (AQ_t 0.49 / AQ_t-1 0.53) |
| SGI: 0.93 (Revenue 9.54b / 10.28b) |
| TATA: -0.11 (NI -1.16b - CFO 1.15b) / TA 21.70b) |
| Beneish M-Score: -3.42 (Cap -4..+1) = AA |
What is the price of CE shares?
As of March 07, 2026, the stock is trading at USD 49.32 with a total of 2,565,374 shares traded.
Over the past week, the price has changed by -1.24%, over one month by -10.08%, over three months by +23.28% and over the past year by -10.46%.
Over the past week, the price has changed by -1.24%, over one month by -10.08%, over three months by +23.28% and over the past year by -10.46%.
Is CE a buy, sell or hold?
Celanese has received a consensus analysts rating of 3.44.
Therefor, it is recommend to hold CE.
- StrongBuy: 5
- Buy: 0
- Hold: 12
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.2 | 26.1% |
| Analysts Target Price | 62.2 | 26.1% |
CE Fundamental Data Overview March 07, 2026
P/E Forward = 10.1729
P/S = 0.6033
P/B = 1.3842
P/EG = 4.4198
Revenue TTM = 9.54b USD
EBIT TTM = -477.0m USD
EBITDA TTM = 292.0m USD
Long Term Debt = 11.39b USD (from longTermDebt, last quarter)
Short Term Debt = 1.20b USD (from shortTermDebt, last quarter)
Debt = 1.47b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 206.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.96b USD (5.76b + Debt 1.47b - CCE 1.26b)
Interest Coverage Ratio = -0.62 (Ebit TTM -477.0m / Interest Expense TTM 769.0m)
EV/FCF = 7.43x (Enterprise Value 5.96b / FCF TTM 803.0m)
FCF Yield = 13.46% (FCF TTM 803.0m / Enterprise Value 5.96b)
FCF Margin = 8.41% (FCF TTM 803.0m / Revenue TTM 9.54b)
Net Margin = -12.15% (Net Income TTM -1.16b / Revenue TTM 9.54b)
Gross Margin = 20.06% ((Revenue TTM 9.54b - Cost of Revenue TTM 7.63b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 21.54%)
Tobins Q-Ratio = 0.27 (Enterprise Value 5.96b / Total Assets 21.70b)
Interest Expense / Debt = 14.57% (Interest Expense 214.0m / Debt 1.47b)
Taxrate = 21.0% (US default 21%)
NOPAT = -376.8m (EBIT -477.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 5.69b / Total Current Liabilities 3.68b)
Debt / Equity = 0.36 (Debt 1.47b / totalStockholderEquity, last quarter 4.05b)
Debt / EBITDA = 0.71 (Net Debt 206.0m / EBITDA 292.0m)
Debt / FCF = 0.26 (Net Debt 206.0m / FCF TTM 803.0m)
Total Stockholder Equity = 4.62b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.21% (Net Income -1.16b / Total Assets 21.70b)
RoE = -25.13% (Net Income TTM -1.16b / Total Stockholder Equity 4.62b)
RoCE = -2.98% (EBIT -477.0m / Capital Employed (Equity 4.62b + L.T.Debt 11.39b))
RoIC = -2.16% (negative operating profit) (NOPAT -376.8m / Invested Capital 17.41b)
WACC = 10.69% (E(5.76b)/V(7.23b) * Re(10.48%) + D(1.47b)/V(7.23b) * Rd(14.57%) * (1-Tc(0.21)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
[DCF] Terminal Value 64.97% ; FCFF base≈694.2m ; Y1≈575.0m ; Y5≈417.8m
[DCF] Fair Price = 44.78 (EV 5.11b - Net Debt 206.0m = Equity 4.91b / Shares 109.6m; r=10.69% [WACC]; 5y FCF grow -20.68% → 2.90% )
EPS Correlation: -79.49 | EPS CAGR: -43.07% | SUE: -1.03 | # QB: 0
Revenue Correlation: -28.05 | Revenue CAGR: -3.69% | SUE: -0.54 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.15 | Chg7d=-0.481 | Chg30d=-0.481 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-12-31): EPS=4.66 | Chg7d=+0.000 | Chg30d=-0.776 | Revisions Net=-14 | Growth EPS=+17.2% | Growth Revenue=-1.9%
EPS next Year (2027-12-31): EPS=5.94 | Chg7d=+0.000 | Chg30d=-0.743 | Revisions Net=-10 | Growth EPS=+27.4% | Growth Revenue=+3.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 8 Down within 30d for Next Quarter)
P/S = 0.6033
P/B = 1.3842
P/EG = 4.4198
Revenue TTM = 9.54b USD
EBIT TTM = -477.0m USD
EBITDA TTM = 292.0m USD
Long Term Debt = 11.39b USD (from longTermDebt, last quarter)
Short Term Debt = 1.20b USD (from shortTermDebt, last quarter)
Debt = 1.47b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 206.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.96b USD (5.76b + Debt 1.47b - CCE 1.26b)
Interest Coverage Ratio = -0.62 (Ebit TTM -477.0m / Interest Expense TTM 769.0m)
EV/FCF = 7.43x (Enterprise Value 5.96b / FCF TTM 803.0m)
FCF Yield = 13.46% (FCF TTM 803.0m / Enterprise Value 5.96b)
FCF Margin = 8.41% (FCF TTM 803.0m / Revenue TTM 9.54b)
Net Margin = -12.15% (Net Income TTM -1.16b / Revenue TTM 9.54b)
Gross Margin = 20.06% ((Revenue TTM 9.54b - Cost of Revenue TTM 7.63b) / Revenue TTM)
Gross Margin QoQ = 17.38% (prev 21.54%)
Tobins Q-Ratio = 0.27 (Enterprise Value 5.96b / Total Assets 21.70b)
Interest Expense / Debt = 14.57% (Interest Expense 214.0m / Debt 1.47b)
Taxrate = 21.0% (US default 21%)
NOPAT = -376.8m (EBIT -477.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 5.69b / Total Current Liabilities 3.68b)
Debt / Equity = 0.36 (Debt 1.47b / totalStockholderEquity, last quarter 4.05b)
Debt / EBITDA = 0.71 (Net Debt 206.0m / EBITDA 292.0m)
Debt / FCF = 0.26 (Net Debt 206.0m / FCF TTM 803.0m)
Total Stockholder Equity = 4.62b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.21% (Net Income -1.16b / Total Assets 21.70b)
RoE = -25.13% (Net Income TTM -1.16b / Total Stockholder Equity 4.62b)
RoCE = -2.98% (EBIT -477.0m / Capital Employed (Equity 4.62b + L.T.Debt 11.39b))
RoIC = -2.16% (negative operating profit) (NOPAT -376.8m / Invested Capital 17.41b)
WACC = 10.69% (E(5.76b)/V(7.23b) * Re(10.48%) + D(1.47b)/V(7.23b) * Rd(14.57%) * (1-Tc(0.21)))
Discount Rate = 10.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
[DCF] Terminal Value 64.97% ; FCFF base≈694.2m ; Y1≈575.0m ; Y5≈417.8m
[DCF] Fair Price = 44.78 (EV 5.11b - Net Debt 206.0m = Equity 4.91b / Shares 109.6m; r=10.69% [WACC]; 5y FCF grow -20.68% → 2.90% )
EPS Correlation: -79.49 | EPS CAGR: -43.07% | SUE: -1.03 | # QB: 0
Revenue Correlation: -28.05 | Revenue CAGR: -3.69% | SUE: -0.54 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.15 | Chg7d=-0.481 | Chg30d=-0.481 | Revisions Net=-8 | Analysts=15
EPS current Year (2026-12-31): EPS=4.66 | Chg7d=+0.000 | Chg30d=-0.776 | Revisions Net=-14 | Growth EPS=+17.2% | Growth Revenue=-1.9%
EPS next Year (2027-12-31): EPS=5.94 | Chg7d=+0.000 | Chg30d=-0.743 | Revisions Net=-10 | Growth EPS=+27.4% | Growth Revenue=+3.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 8 Down within 30d for Next Quarter)